World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
102
Citations
34623
World Ranking
7720
National Ranking
4017

Overview

Alessandra Ferrajoli is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a specialization in Genetics, Hematology, Pathology and Forensic Medicine, Immunology, and Public Health, Environmental and Occupational Health.

Their work extensively covers topics related to Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, Immunodeficiency and Autoimmune Disorders, and Advanced Breast Cancer Therapies.

Frequent co-authors include:

  • Nitin Jain
  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Elias Jabbour
  • William G. Wierda

Common venues where Alessandra Ferrajoli has published are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia
  • Journal of Clinical Oncology
  • American Journal of Hematology

The following are some recent significant papers published by Alessandra Ferrajoli or involving their collaboration:

  • "Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia", 2022, New England Journal of Medicine
  • "10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial", 2020, The Lancet Haematology
  • "Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens", 2020, Haematologica
  • "Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia", 2021, Blood Cancer Journal
  • "Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia", 2022, Journal of Clinical Oncology

Best Publications

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

    Guillermo Garcia-Manero;Hui Yang;Carlos Bueso-Ramos;Alessandra Ferrajoli

  • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

    Alessandra Ferrajoli;Bang-Ning Lee;Ellen J. Schlette;Susan M. O'Brien

  • Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

    Deborah A. Thomas;Susan O'Brien;Stefan Faderl;Guillermo Garcia-Manero

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

    Elihu Estey;Guillermo Garcia-Manero;Alessandra Ferrajoli;Stefan Faderl

  • Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

    Farhad Ravandi;Eli Estey;Dan Jones;Stefan Faderl

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

    Jan A Burger;Michael J Keating;William G Wierda;Elena Hartmann

  • microRNA Therapeutics in Cancer — An Emerging Concept

    Maitri Y. Shah;Alessandra Ferrajoli;Anil K Sood;Gabriel Lopez-Berestein

  • Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

    Karen W.L. Yee;Zhihong Zeng;Marina Konopleva;Srdan Verstovsek

  • First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia

    Farhad Ravandi;Susan O'Brien;Deborah Thomas;Stefan Faderl

  • Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

    Preetesh Jain;Preetesh Jain;Michael Keating;William G Wierda;Zeev Estrov

  • Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

    Jorge E Cortes;Moshe Talpaz;Francis Giles;Susan O'Brien

  • Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.

    Susan M. O'Brien;Hagop M. Kantarjian;Deborah A. Thomas;Jorge Cortes

  • The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia

    Francis J. Giles;Francis J. Giles;Gautam Borthakur;Farhad Ravandi;Stefan Faderl

  • Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Jorge E. Cortes;Dan Jones;Susan O'Brien;Elias Jabbour

  • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Commentary

    Thomas S. Lin;Alessandra Ferrajoli;Bang-Ning Lee;Ellen J. Schlette

Frequent Co-Authors

William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine who seek flexible learning options, a variety of online degrees are available across the nursing and healthcare fields. These programs are designed to support working professionals or those looking for affordable study plans as they move toward a rewarding career in healthcare.

Nurses can advance their academic credentials without breaking the bank by exploring the cheapest phd nursing programs, making it possible to gain advanced specializations and move into leadership roles. Similarly, registered nurses aiming to earn a bachelor’s degree can find value with the cheapest online rn to bsn programs, which offer a practical and economical path to career progression.

For those changing careers, direct entry msn programs for non-nurses online allow individuals with non-nursing backgrounds to enter the nursing profession at the master’s level efficiently. Meanwhile, aspiring nurses looking for the quickest way to enter the field might explore online adn programs—an accessible entry point into nursing practice.

These diverse online degree options can make healthcare careers more attainable, offering flexibility, affordability, and multiple pathways to success.

Best Scientists Citing Alessandra Ferrajoli

Trending Scientists